Patients With FracturesPhase 4OsteogenonNCT07210281
Osteogenon in Orthopedics and Traumatology
A Phase 4 study testing received an ossein-hydroxyapatite complex in people with Patients With Fractures, run by University of Opole at 1 site in Poland.
Trial summary
The aim of this study was to evaluate the supportive effect of the ossein-hydroxyapatite complex in fracture healing. The investigators hypothesized that the ossein-hydroxyapatite complex would positively impact fracture healing outcomes.The assessment covers clinical, radiological and biomechanical parameters. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Patients With Fractures
- What is being tested?
- received an ossein-hydroxyapatite complex
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 sitePoland
- Study dates
- 1 Nov 2024to 30 Dec 2027
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- no contraindications to taking Osteogenon
- a follow-up period of more than 3 months after treatment completion
- complete medical and radiological records
- a written informed consent
- not taking any other medications that could affect bone tissue remodeling
- not taking other medications that interact with Osteogenon
- no other limb pathologies (inflammatory or neurogenic)
- absence of comorbidities that could affect bone union
Who cannot join
- age under 18 years or over 85 years
- hypersensitivity to the active ingredient or to any of the excipients
- severe renal failure and dialysis therapy
- hypercalcemia
- hypercalciuria
- calcium-based kidney stones or tissue calcifications
Show all 16Show fewer
- a follow-up period shorter than 3 months after treatment completion
- a lack of informed consent
- a lack of cooperation with the patient
- absent or incomplete medical and radiological records
- taking medications that could affect bone tissue remodeling
- taking medications that may interact with Osteogenon (e.g. thiazide diuretics)
- metabolic disorders
- post-traumatic skeletal deformities
- neuromuscular disorders
- post-inflammatory deformities
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Poland1 site, 1 recruiting
- Recruiting
University Clinical Hospital in Opole
Opole, Opole Voivodeship, 46-020
Piotr Morasiewicz, PROF, +48504549666, piotr.morasiewicz@uni.opole.pl
Monika Zaborska, +48692706595, zaborska.monika.pl@gmail.com
About this study
Official title: The Use of Ossein-hydroxyapatite Complex as an Adjunctive Treatment in Orthopedics and Traumatology
The aim of this study was to evaluate the supportive effect of the ossein-hydroxyapatite complex in fracture healing. The investigators hypothesized that the ossein-hydroxyapatite complex would positively impact fracture healing outcomes.The assessment covers clinical, radiological and biomechanical parameters.
Read the detailed description
The role of ossein-hydroxyapatite complex in fracture healing requires further research.
The aim of the study was to evaluate the effect of ossein-hydroxyapatite complex (Osteogenon) as an adjunctive treatment on the outcome of conservative and surgical fractures treatment via comprehensive clinical, radiological and biomechanical assessments. The investigators aimed to reject the null hypothesis of the absence of beneficial effect of ossein-hydroxyapatite complex on fractures treatment outcomes. This would fill the existing gap in the scientific literature and enable a more widespread use of Osteogenon in the treatment of fractures in many trauma centers.
Patients in the study group with fractures received an ossein-hydroxyapatite complex (830 milligram [mg] of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily.
The drug Osteogenon used in our study had been approved for fracture treatment. The study was conducted in accordance with the Declaration of Helsinki and all applicable laws and regulations. All patients had provided their written informed consent and were informed of a voluntary nature of their participation in this study.
Patients participating in the study, both in the study and control groups, had to meet the inclusion criteria. The randomization method used was to evenly recruit the study and control groups as patients who met the inclusion criteria were recruited. Randomization took into account the equal distribution of gender and age in both groups.
Patients from both the experimental and control groups received the same recommendations regarding rehabilitation and had the same clinical and radiological follow-up protocol.
The following clinical, biomechanical and radiological parameters were assessed in the study: the period of immobilization, rate of bone union, analgesic use at the beginning of treatment, analgesic use during the follow-up, time to achieving pain relief, pain in 100 millimeter [mm] Visual Analogue Scale (VAS), number of patients declaring pain relief, rate of complications, time to resuming normal physical activity, grip strength, muscle strength during joint movement.
The period of immobilization was defined as the total number of days during which cast immobilization was maintained. The time to resuming normal physical activity was expressed in days and defined as the period from injury to return to work or school and normal everyday activities.
The rate of bone union was determined based on the percentage of patients who achieved clinical and radiological criteria of bone union. The radiological criteria of bone union were the presence of a minimum of 3 out of 4 consolidated cortical bone layers or trabecular transition between bone fragments on X-rays in 2 views. Clinical bone union was defined as the lack of pathological mobility, pain, or deformity during attempts to perform movements in the wrist area at the fracture site. Nonunion was defined as failure to meet the above criteria for 6 months after the fracture .
The investigators also assessed the number of patients on any analgesics (paracetamol, ibuprofen, non-steroidal anti-inflammatory drugs, tramadol) at the beginning of treatment and at the final follow-up. During regular follow-up visits, patients were asked about their pain intensity using the NRS (Numerical Rating Scale). A period of discontinuation of any pain medication was equivalent to a patient rating their pain level as 0 on the NRS. Time to achieving pain relief was expressed in days and defined as the period from the beginning to end of taking any analgesic drugs.
Complications were assessed based on medical and radiological records. The evaluated complications included nonunion, delayed bone union, fragment displacement, persistent pain, persistent swelling, limited range of motion, vascular damage, nerve damage, the need for revision surgery or repeated reduction and immobilization.
- Conditions
- Patients With Fractures
- Being tested
- received an ossein-hydroxyapatite complex
- Keywords
- fractures, Osteogenon, ossein-hydroxyapatite complex, distal radius fractures, lower leg fracture, proximal humerus fractures
- Medical subject headings
- Fractures, Bone, Wrist Fractures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
received an ossein-hydroxyapatite complexDrug
Patients in the study group with fractures received an ossein-hydroxyapatite complex (830 mg of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily.
| Study group | Role | What they receive |
|---|---|---|
| Osteogenon | Experimental | received an ossein-hydroxyapatite complex Receives: Drug: received an ossein-hydroxyapatite complex |
| Control | No intervention | did not receive an ossein-hydroxyapatite complex |
What is being measured
The primary outcome is the main question the study is designed to answer.
period of bone union
assessed by data linkage to medical and radiological records
Measured: at 6 months after randomisation
Achieving bone union
assessed by data linkage to medical and radiological records
Measured: at 6 months after randomisation
Secondary outcomes (1)
pain assessment
100mm Visual Analogue Scale (VAS)
- 0 mm indicates "no pain"
- 100 mm indicates "worst imaginable pain"
- Higher scores on the VAS indicate a worse outcome (greater pain intensity).
Measured: at 6 months after randomisation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2025
- Study start1 Nov 2024
- Primary completion2 Feb 2027 (estimated)
- Study completion30 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Patients With FracturesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Opole
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Piotr Morasiewicz, University of Opole
- Investigators
- Marek Gierlotka, PROF, Study chair, University of Opole
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07210281
- Sponsor's protocol ID
- P-2025-003
- Other IDs
- P-2025-004
- Acronym
- Osteogenon
- Status last verified
- Nov 2025
- First submitted
- 29 Sep 2025
- Last updated
- 28 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The data collected during our study are our own efforts and will be used to prepare our publications. Other authors are encouraged to conduct their own research.
Publications
Morasiewicz P, Zaborska M, Sobczak M, Tomczyk L, Leyko P, Bobinski A, Kochanska-Bieri J, Pili D, Kazubski K. The Use of Osteogenon as an Adjunctive Treatment in Lower Leg Fractures. Pharmaceuticals (Basel). 2024 Nov 14;17(11):1531. doi: 10.3390/ph17111531.
PubMed 39598441Morasiewicz P, Zaborska M, Sobczak M, Tomczyk L, Pili D, Kazubski K, Leyko P. The Use of Ossein-Hydroxyapatite Complex in Conjunction with the Ilizarov Method in the Treatment of Tibial Nonunion. J Clin Med. 2025 May 12;14(10):3353. doi: 10.3390/jcm14103353.
PubMed 40429349
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Use of Ossein-hydroxyapatite Complex as an Adjunctive Treatment in Orthopedics and Traumatology
- ClinicalTrials.gov ID
- NCT07210281
- Acronym / sponsor ID
- Osteogenon / P-2025-003
- Conditions
- Patients With Fractures
- Keywords
- fractures, Osteogenon, ossein-hydroxyapatite complex, distal radius fractures, lower leg fracture, proximal humerus fractures
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- University of OpoleUniversity, hospital or other
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 2 Feb 2027 (estimated)
- Study completion
- 30 Dec 2027 (estimated)
- First posted
- 7 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to evaluate the supportive effect of the ossein-hydroxyapatite complex in fracture healing. The investigators hypothesized that the ossein-hydroxyapatite complex would positively impact fracture healing outcomes.The assessment covers clinical, radiological and biomechanical parameters.
Detailed description
The role of ossein-hydroxyapatite complex in fracture healing requires further research.
The aim of the study was to evaluate the effect of ossein-hydroxyapatite complex (Osteogenon) as an adjunctive treatment on the outcome of conservative and surgical fractures treatment via comprehensive clinical, radiological and biomechanical assessments. The investigators aimed to reject the null hypothesis of the absence of beneficial effect of ossein-hydroxyapatite complex on fractures treatment outcomes. This would fill the existing gap in the scientific literature and enable a more widespread use of Osteogenon in the treatment of fractures in many trauma centers.
Patients in the study group with fractures received an ossein-hydroxyapatite complex (830 milligram [mg] of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily.
The drug Osteogenon used in our study had been approved for fracture treatment. The study was conducted in accordance with the Declaration of Helsinki and all applicable laws and regulations. All patients had provided their written informed consent and were informed of a voluntary nature of their participation in this study.
Patients participating in the study, both in the study and control groups, had to meet the inclusion criteria. The randomization method used was to evenly recruit the study and control groups as patients who met the inclusion criteria were recruited. Randomization took into account the equal distribution of gender and age in both groups.
Patients from both the experimental and control groups received the same recommendations regarding rehabilitation and had the same clinical and radiological follow-up protocol.
The following clinical, biomechanical and radiological parameters were assessed in the study: the period of immobilization, rate of bone union, analgesic use at the beginning of treatment, analgesic use during the follow-up, time to achieving pain relief, pain in 100 millimeter [mm] Visual Analogue Scale (VAS), number of patients declaring pain relief, rate of complications, time to resuming normal physical activity, grip strength, muscle strength during joint movement.
The period of immobilization was defined as the total number of days during which cast immobilization was maintained. The time to resuming normal physical activity was expressed in days and defined as the period from injury to return to work or school and normal everyday activities.
The rate of bone union was determined based on the percentage of patients who achieved clinical and radiological criteria of bone union. The radiological criteria of bone union were the presence of a minimum of 3 out of 4 consolidated cortical bone layers or trabecular transition between bone fragments on X-rays in 2 views. Clinical bone union was defined as the lack of pathological mobility, pain, or deformity during attempts to perform movements in the wrist area at the fracture site. Nonunion was defined as failure to meet the above criteria for 6 months after the fracture .
The investigators also assessed the number of patients on any analgesics (paracetamol, ibuprofen, non-steroidal anti-inflammatory drugs, tramadol) at the beginning of treatment and at the final follow-up. During regular follow-up visits, patients were asked about their pain intensity using the NRS (Numerical Rating Scale). A period of discontinuation of any pain medication was equivalent to a patient rating their pain level as 0 on the NRS. Time to achieving pain relief was expressed in days and defined as the period from the beginning to end of taking any analgesic drugs.
Complications were assessed based on medical and radiological records. The evaluated complications included nonunion, delayed bone union, fragment displacement, persistent pain, persistent swelling, limited range of motion, vascular damage, nerve damage, the need for revision surgery or repeated reduction and immobilization.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Osteogenon | Experimental | Drug: received an ossein-hydroxyapatite complexreceived an ossein-hydroxyapatite complex |
| Control | No intervention | –did not receive an ossein-hydroxyapatite complex |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- no contraindications to taking Osteogenon
- a follow-up period of more than 3 months after treatment completion
- complete medical and radiological records
- a written informed consent
- not taking any other medications that could affect bone tissue remodeling
Key exclusion criteria (16 listed)
- age under 18 years or over 85 years
- hypersensitivity to the active ingredient or to any of the excipients
- severe renal failure and dialysis therapy
- hypercalcemia
- hypercalciuria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| received an ossein-hydroxyapatite complexPatients in the study group with fractures received an ossein-hydroxyapatite complex (830 mg of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily. | Drug | Osteogenon |
Primary outcome
period of bone union
Time frame: at 6 months after randomisation
assessed by data linkage to medical and radiological records
Achieving bone union
Time frame: at 6 months after randomisation
assessed by data linkage to medical and radiological records
1 secondary outcome
pain assessment
Time frame: at 6 months after randomisation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2025.
- Background: PubMed 39598441Morasiewicz P, Zaborska M, Sobczak M, Tomczyk L, Leyko P, Bobinski A, Kochanska-Bieri J, Pili D, Kazubski K. The Use of Osteogenon as an Adjunctive Treatment in Lower Leg Fractures. Pharmaceuticals (Basel). 2024 Nov 14;17(11):1531. doi: 10.3390/ph17111531.
- Background: PubMed 40429349Morasiewicz P, Zaborska M, Sobczak M, Tomczyk L, Pili D, Kazubski K, Leyko P. The Use of Ossein-Hydroxyapatite Complex in Conjunction with the Ilizarov Method in the Treatment of Tibial Nonunion. J Clin Med. 2025 May 12;14(10):3353. doi: 10.3390/jcm14103353.
- Individual participant dataSharing planned: No. The data collected during our study are our own efforts and will be used to prepare our publications. Other authors are encouraged to conduct their own research.
Related trials for Patients With Fractures
RecruitingObservational study
Duration of Immobilization After Reverse Total Arthroplasty for Proximal Humerus Fractures
Proximal Humeral Fracture, Reverse Total Shoulder Arthroplasty
RecruitingObservational study
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
Breast Cancer
Not yet recruiting
Lumbar Erector Spinae Plane Block Versus PENG Block for Hip Fracture Surgery
Femur Neck Fracture, Hip Fractures
Active, not recruitingPhase 2
Trial of Combined Radiotherapy and Vertebroplasty for Patients With Painful Metastatic Spinal Lesions
Spinal Metastases
Active, not recruiting
Lumbar-Sacral Plexus Block vs Fascia Iliaca Block Plus Low-Dose Spinal Anesthesia for Femoral Neck Fracture Surgery
Femoral Neck Fractures, Nerve Block
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marek Gierlotka, PROF study chair
University of Opole
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing received an ossein-hydroxyapatite complex in people with Patients With Fractures, run by University of Opole at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Piotr Morasiewicz, PROF (+48504549666, piotr.morasiewicz@uni.opole.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
period of bone union (time frame: at 6 months after randomisation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07210281, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2025.